Study S000372

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT02648204
Acronym: SUSTAIN 7
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 1201
Start: 2016-01-06
Primary completion: 2017-04-10
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:semaglutide; DRUG:Dulaglutide
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2014-005375-91; OTHER:U1111-1164-8495; NIH:2014

Registered primary outcomes

Change in HbA1c [Week 0, week 40]

Linked records (13)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012919	Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison. Osumili B, Diabetes research and clinical practice	2024	Other trial	PMID 38777128 DOI	cites ClinicalTrials.gov:NCT02648204; registry reference DERIVED:38777128
R0015927	Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. DeSouza C, The Journal of clinical endocrinology and metabolism	2020	Randomized trial	PMID 31769496 DOI	cites ClinicalTrials.gov:NCT02648204; registry reference DERIVED:31769496
R0018021	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. Pratley RE, BMJ open	2020	Other trial	PMID 33199417 DOI	cites ClinicalTrials.gov:NCT02648204; registry reference DERIVED:33199417
R0009827	GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES. Rodbard HW, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists	2019	Other trial	PMID 30865526 DOI	registry reference BACKGROUND:30865526
R0012485	Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials. Jendle J, Diabetes, obesity & metabolism	2019	Other trial	PMID 31215727 DOI	cites ClinicalTrials.gov:NCT02648204; cites EudraCT:2014-005375-91; registry reference DERIVED:31215727
R0013158	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Aroda VR, Diabetes & metabolism	2019	Other trial	PMID 30615985 DOI	registry reference RESULT:30615985
R0013463	The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Malkin SJP, Advances in therapy	2019	Nonrandomized study	PMID 31168765 DOI	registry reference BACKGROUND:31168765
R0016078	Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Viljoen A, Diabetes, obesity & metabolism	2019	Nonrandomized study	PMID 30362224 DOI	registry reference RESULT:30362224
R0018590	Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. Johansen P, PharmacoEconomics - open	2019	Nonrandomized study	PMID 30927241 DOI	registry reference BACKGROUND:30927241
R0014565	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Pratley RE, The lancet. Diabetes & endocrinology	2018	Randomized trial	PMID 29397376 DOI	cites ClinicalTrials.gov:NCT02648204; registry reference RESULT:29397376
R0019899	Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. Wilkinson L, Diabetes therapy : research, treatment and education of diabetes and related disorders	2018	Randomized trial	PMID 29557057 DOI	registry reference RESULT:29557057
R0020680	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Ahmann AJ, Diabetes care	2018	Randomized trial	PMID 29246950 DOI	registry reference RESULT:29246950
R0025617	Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. Sharma R, Current medical research and opinion	2018	Systematic review	PMID 29764222 DOI	registry reference RESULT:29764222